Sort
10,766 grants matching “checkpoint inhibitor”
Targeting Ribosomal Biogenesis in Prostate Cancer
$163,671Everardo Macias · Duke University · K22 · FY2017 · CA
Impact of BRCA1-mTORC2 interaction on breast cancer response to DNA damage and ch
$163,669Nicholas Taylor Woods · University Of Nebraska Medical Center · R21 · FY2015 · CA
Applications of a robust, vector-free intracellular delivery platform for immune cells
$163,570Scott McNabb Loughhead · Sqz Biotechnologies Company, Inc. · R44 · FY2018 · GM
Abrogating a survival pathway in early colon cancer cells
$163,507Nan Gao · Rutgers The State Univ Of Nj Newark · R21 · FY2014 · CA
Harnessing Exercise to Enhance Immunity and Boost Immunotherapy Outcomes in Patients with Lung Cancer
$163,448Dong-Woo Kang · Dana-Farber Cancer Inst · K99 · FY2024 · CA
Immunologic Approaches to Ovarian Cancer
$163,445Paul J Sabbatini · Sloan-Kettering Inst Can Research · P01 · FY2019 · CA
Evaluating a multimodality platform of tissue, blood and advanced imaging-based biomarkers to predict response to neoadjuvant immunotherapy and radiotherapy in melanoma
$163,310Devarati Mitra · University Of Tx Md Anderson Can Ctr · R03 · FY2025 · TR
CD40 Immunotherapy Effect on the Cardiac Immune Landscape and Response to Myocardial Disease
$163,255Jesus Jimenez · Washington University · K08 · FY2024 · HL
Durvalumab in Combination with Olaparib in Non-Small Cell Lung Cancer
$163,158Arun Rajan · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA
Project 3 - Genome-Guided Therapeutic Vulnerabilities in Esophageal Cancer
$163,031Kwok Kin Wong · Columbia University Health Sciences · P01 · FY2022 · CA
Roles of CD47 Signaling in Tumor Immunology
$163,015David D Roberts · Division Of Clinical Sciences - Nci · ZIA · FY2022 · CA
CD40 Immunotherapy Effect on the Cardiac Immune Landscape and Response to Myocardial Disease
$162,935Jesus Jimenez · Washington University · K08 · FY2025 · HL
Microtubule Regulation
$162,658Don W. Cleveland · Ludwig Institute For Cancer Res Ltd · R01 · FY2009 · GM
PHYSIOLOGICAL MEDIATORS OF GRANULOSA CELL APOPTOSIS
$162,631University Of Notre Dame · R01 · FY2000 · HD
Systems biology dissection of the road to T cell exhaustion within the tumor microenvironment to identify novel targets for tumor immunotherapy
$162,450Ann B Hill · Oregon Health & Science University · R21 · FY2019 · CA
Determining how autophagy mediates resistance to cancer therapies
$162,450George Victor Thomas · Oregon Health & Science University · R21 · FY2019 · CA
Immuno-Oncology
$162,194Jose R Conejo-Garcia · H. Lee Moffitt Cancer Ctr & Res Inst · P30 · FY2022 · CA
Exploring biomarkers of clinical benefit to VEGFR inhibitor combined with PD-L1 inhibitor in recurrent/metastatic Adenoid Cystic Carcinoma
$162,000Renata Ferrarotto · University Of Tx Md Anderson Can Ctr · R03 · FY2023 · DE
Exploring biomarkers of clinical benefit to VEGFR inhibitor combined with PD-L1 inhibitor in recurrent/metastatic Adenoid Cystic Carcinoma
$162,000Renata Ferrarotto · University Of Tx Md Anderson Can Ctr · R03 · FY2022 · DE
The Houston Center for Acquired Resistance Research (H-CARR)
$162,000Jeffrey Nicholas Myers · University Of Tx Md Anderson Can Ctr · U54 · FY2023 · CA
Cervical cancer derived xenografts (PDX) and organoid raft cultures to evaluate pathway specific therapeutic agents.
$161,494Nilam Sanjib Banerjee · University Of Alabama At Birmingham · R21 · FY2020 · CA
Intratumoral immunotherapy to enhance T cell infiltration and augment immune checkpoint blockade responses across molecular subtypes of breast cancer
$161,486Erika J Crosby · Duke University · K22 · FY2022 · CA
Overcoming immune checkpoint inhibition with therapeutic plasma exchange and radiotherapy in melanoma
$161,411Sean S Park · Mayo Clinic Rochester · R21 · FY2022 · CA
PD-1 Blockade and Neoantigen-Specific T Cell Immunity
$161,348Gerald P Linette · University Of Pennsylvania · R21 · FY2018 · CA
Myeloid Syk promotes tumor immunosuppression and inhibits anti-tumor adaptive immunity
$161,230Shweta Joshi · University Of California, San Diego · K22 · FY2021 · CA